4897-54-5Relevant articles and documents
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degene
Palanki, Moorthy S. S.,Akiyama, Hideo,Campochiaro, Peter,Cao, Jianguo,Chow, Chun P.,Dellamary, Luis,Doukas, John,Fine, Richard,Gritzen, Colleen,Hood, John D.,Hu, Steven,Kachi, Shu,Kang, Xinshan,Klebansky, Boris,Kousba, Ahmed,Lohse, Dan,Chi, Ching Mak,Martin, Michael,McPherson, Andrew,Pathak, Ved P.,Renick, Joel,Soll, Richard,Umeda, Naoyasu,Yee, Shiyin,Yokoi, Katsutoshi,Zeng, Binqi,Zhu, Hong,Noronha, Glenn
, p. 1546 - 1559 (2008/12/21)
Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeti
PYRIMIDINE COMPOUNDS AND METHODS OF USE
-
Page/Page column 114-115, (2010/11/24)
The invention provides pyrimidine compounds having formula (A): The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.